---

完整標題：Pfizer Says COVID-19 Vaccine Shows '100% Efficacy' In Adolescents
發稿單位：NPR
發稿時間：Updated March 31, 20218:17 AM ET
原文連結：https://t.ly/StJq
原文:
New clinical trials showed that Pfizer's COVID-19 vaccine elicits "100%
efficacy and robust antibody responses" in adolescents from 12 to 15 years
old, the drug company announced Wednesday. The trial included 2,260
participants; the results are even better than earlier responses from
participants ages 16 to 25.

Pfizer and its vaccine partner BioNTech said they will submit the results "as
soon as possible" to the U.S. Food and Drug Administration and the European
Medicines Agency, asking regulators to expand their authorizations for the
vaccine's use in young people.

Pfizer will submit the data "in the coming weeks," Pfizer CEO and Chairman
Albert Bourla said in a news release about the trial. Calling the results
encouraging, he added that the company is acting "with the hope of starting
to vaccinate this age group before the start of the next school year."
SHOTS - HEALTH NEWS
How Is The COVID-19 Vaccination Campaign Going In Your State?
During the clinical trial, 18 people who were in the placebo group developed
COVID-19, while none of the people in the vaccinated group did. Blood tests
showed a strong immune system response one month after participants received
the second vaccine dose, according to a summary of test data released by
Pfizer.

As for potential side effects, Pfizer said the vaccine was tolerated well in
the late-stage trial.

--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 64.106.111.101 (美國)
※ 文章代碼(AID): #1WPEwgpK (nCoV2019)
※ 文章網址: https://www.ptt.cc/bbs/nCoV2019/M.1617227434.A.CD4.html